|
1
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heimbach JK, Kulik LM, Finn RS, Sirlin CB,
Abecassis MM, Roberts LR, Zhu AX, Murad MH and Marrero JA: AASLD
guidelines for the treatment of hepatocellular carcinoma.
Hepatology. 67:358–380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
European Association for the Study of the
Liver, . EASL clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie DY, Ren ZG, Zhou J, Fan J and Gao Q:
2019 Chinese clinical guidelines for the management of
hepatocellular carcinoma: Updates and insights. Hepatobiliary Surg
Nutr. 9:452–463. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Facciorusso A, Di Maso M and Muscatiello
N: Microwave ablation versus radiofrequency ablation for the
treatment of hepatocellular carcinoma: A systematic review and
meta-analysis. Int J Hyperthermia. 32:339–344. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cerrito L, Pallozzi M, Urbani I, Archilei
S, Miliani S, Creta E, Stella L, Gasbarrini A and Ponziani FR:
Unexpected therapeutic implications: The abscopal effect in the
management of hepatocellular carcinoma. Cancers (Basel).
18:4082026. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Formenti SC and Demaria S: Combining
radiotherapy and cancer immunotherapy: A paradigm shift. J Natl
Cancer Inst. 105:256–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Greten TF, Mauda-Havakuk M, Heinrich B,
Korangy F and Wood BJ: Combined locoregional-immunotherapy for
liver cancer. J Hepatol. 70:999–1007. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X,
Sun M, Wen W, Dai X, Yang M, et al: PD-1 blockade boosts
radiofrequency ablation-elicited adaptive immune responses against
tumor. Clin Cancer Res. 22:1173–1184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zerbini A, Pilli M, Penna A, Pelosi G,
Schianchi C, Molinari A, Schivazappa S, Zibera C, Fagnoni FF,
Ferrari C and Missale G: Radiofrequency thermal ablation of
hepatocellular carcinoma liver nodules can activate and enhance
tumor-specific T-cell responses. Cancer Res. 66:1139–1146. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ali MY, Grimm CF, Ritter M, Mohr L,
Allgaier HP, Weth R, Bocher WO, Endrulat K, Blum HE and Geissler M:
Activation of dendritic cells by local ablation of hepatocellular
carcinoma. J Hepatol. 43:817–822. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nobuoka D, Motomura Y, Shirakawa H,
Yoshikawa T, Kuronuma T, Takahashi M, Nakachi K, Ishii H, Furuse J,
Gotohda N, et al: Radiofrequency ablation for hepatocellular
carcinoma induces glypican-3 peptide-specific cytotoxic T
lymphocytes. Int J Oncol. 40:63–70. 2012.PubMed/NCBI
|
|
16
|
Leuchte K, Staib E, Thelen M, Gödel P,
Lechner A, Zentis P, Garcia-Marquez M, Waldschmidt D, Datta RR,
Wahba R, et al: Microwave ablation enhances tumor-specific immune
response in patients with hepatocellular carcinoma. Cancer Immunol
Immunother. 70:893–907. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Zhang Q, Lu Q, Cheng Z, Liu F, Han
Z, Yu X, Yu J and Liang P: Microwave ablation combined with
apatinib and camrelizumab in patients with advanced hepatocellular
carcinoma: A single-arm, preliminary study. Front Immunol.
13:10239832022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bo XW, Sun LP, Yu SY and Xu HX: Thermal
ablation and immunotherapy for hepatocellular carcinoma: Recent
advances and future directions. World J Gastrointest Oncol.
13:1397–1411. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chu KF and Dupuy DE: Thermal ablation of
tumours: Biological mechanisms and advances in therapy. Nat Rev
Cancer. 14:199–208. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duffy AG, Ulahannan SV, Makorova-Rusher O,
Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T,
ElGindi M, et al: Tremelimumab in combination with ablation in
patients with advanced hepatocellular carcinoma. J Hepatol.
66:545–551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dumolard L, Ghelfi J, Roth G, Decaens T
and Macek Jilkova Z: Percutaneous ablation-induced immunomodulation
in hepatocellular carcinoma. Int J Mol Sci. 21:43982020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Pembrolizumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J,
Shao G, Zhang Y, Xu L, Yin T, et al: Camrelizumab in combination
with apatinib in patients with advanced hepatocellular carcinoma
(RESCUE): A nonrandomized, open-label, phase II trial. Clin Cancer
Res. 27:1003–1011. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He MK, Liang RB, Zhao Y, Xu YJ, Chen HW,
Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, et al: Lenvatinib,
toripalimab, plus hepatic arterial infusion chemotherapy versus
lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv
Med Oncol. 13:175883592110027202021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai
Y, Liu T, Zhou Q, Zhao J, Shu Y, et al: Tislelizumab in Chinese
patients with advanced solid tumors: An open-label,
non-comparative, phase 1/2 study. J Immunother Cancer.
8:e0004372020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hoy SM: Sintilimab: First global approval.
Drugs. 79:341–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
National Cancer Institute (NCI), . Common
terminology criteria for adverse events (CTCAE) version 5.0. Cancer
Therapy Evaluation Program. NCI; Bethesda, MD: 2017
|
|
29
|
Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie
J, Wang X, Hao C, Yin Y, Wang S, et al: Chinese society of clinical
oncology (CSCO) breast cancer guidelines 2022. Transl Breast Cancer
Res. 3:132022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH,
Taki-Eldin A and Zheng SS: Selective recruitment of regulatory T
cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor
progression and predicts poor prognosis. PLoS One. 6:e246712011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B,
Zhang Z, Yang H, Zhang H, Zhou C, et al: Increased regulatory T
cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY,
Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of
regulatory and cytotoxic T cells is associated with prognosis of
hepatocellular carcinoma after resection. J Clin Oncol.
25:2586–2593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moeini A, Torrecilla S, Tovar V, Montironi
C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol
R, et al: An immune gene expression signature associated with
development of human hepatocellular carcinoma identifies mice that
respond to chemopreventive agents. Gastroenterology.
157:1383–1397.e11. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yeung OWH, Lo CM, Ling CC, Qi X, Geng W,
Li CX, Ng KTP, Forbes SJ, Guan XY, Poon RTP, et al: Alternatively
activated (M2) macrophages promote tumour growth and invasiveness
in hepatocellular carcinoma. J Hepatol. 62:607–616. 2015.
View Article : Google Scholar : PubMed/NCBI
|
